Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.
Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.
Large language models, also known as foundation models, are AI systems that learn fundamental knowledge from massive amounts of general data, and then apply that knowledge to accomplish new tasks—a process called transfer learning. These systems have recently gained mainstream attention with the release of ChatGPT, a chatbot built on a model from OpenAI.
Amplo Biotechnology's development of AMP-201 builds upon it's progression of AMP-101, an AAV-DOK7 gene therapy targeting Dok-7 congenital myasthenic syndrome, which Amplo expects to bring to clinical trial in 2024. Upon demonstrating initial safety and efficacy, the company plans to expand into other neuromuscular conditions, leveraging the vast potential of AMP-101 and AMP-201 to significantly enhance the quality of life for the majority of CMS patients.
“Given the unmet medical need for patients with recurrent/metastatic HPV16+ head and neck cancers, we are thrilled to share the preliminary data on HB-200 in combination with pembrolizumab as they show a robust improvement in objective response rate and prolonged tumor control compared to pembrolizumab alone,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Efficacy, immunogenicity and safety data observed in our HB-200 program to-date support our decision to progress to a pivotal trial of HB-200 in combination with pembrolizumab as 1st-line treatment for these patients. The data also underscore the scalability of our arenaviral platform across a range of cancers.”
Novan conducted a deliberate and thorough review of its commercial and development portfolio of assets to determine a path to optimally deploy capital and maximize shareholder value.
Pascal Prigent, CEO of GENFIT commented: “We are excited to be announcing this licensing deal which marks an additional milestone in the execution of our development strategy in liver diseases with high unmet medical needs. ACLF is a complex disorder that will likely require the combination of different approaches and with this acquisition, we continue to strengthen our leadership in this indication. We now have a unique portfolio of three differentiated clinical stage programs in ACLF. Considering its liver-centric activity, the potential for multi-organ benefits and the breadth of evidence supporting further development in ACLF, we strongly believe in the potential of SRT-015.”
To date, the ACTISAVE study has enrolled more than 300 patients across 10 countries in the world. Out of them, 100 have been treated with thrombolysis with thrombectomy, reaching the target for the first futility analysis. The Independent Data Meeting Committee (IDMC) will gather in Q4 2023 to confirm safety and ascertain that preliminary results are aligned with the initial trial assumptions notes Acticor Biotech.
Immunoassays are biochemical tests designed to determine the presence and concentration of a particular micro or macro molecule or chemical, often in a solution such as serum, plasma or cell culture fluid with antibody or antigen reagents.
Antibodies are Y-shaped proteins formed by human and animal immune functions reacting to unknown substances (antigens) like viruses, toxins, and bacteria. Antibodies respond to specific antigens, tying spots on the antigen and antibody acting as a lock and key. With the help of...
TMRW’s technology provides the world’s first and only fully automated specimen management platform (CryoRobot) that identifies, tracks, and manages frozen eggs and embryos - central to almost every IVF journey. Vios Fertility Institute’s Chicago lab was the first in the world to adopt this revolutionary technology in early 2021.
Bioretec’s target is to receive the CE mark and to introduce the bioresorbable magnesium alloy trauma screw into the markets in the European Union during 2022.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
